Investing
CapEx
Year-over-year, this metric declined by 15.0%, from $10.70M to $9.10M. Over 3 years (FY 2021 to FY 2025), CapEx shows an upward trend with a 15.9% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
Detailed definition
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Peer comparison
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
Metric ID:
capital_expendituresHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.30M | $5.70M | $8.90M | $7.60M | $8.80M | $1.80M | $8.50M | $6.80M | $7.60M | $5.40M | $11.20M | $11.60M | $8.10M | $7.30M | $10.70M | $12.50M | $13.20M | $0.00 | $9.10M |
| QoQ Change | — | +32.6% | +56.1% | -14.6% | +15.8% | -79.5% | +372.2% | -20.0% | +11.8% | -28.9% | +107.4% | +3.6% | -30.2% | -9.9% | +46.6% | +16.8% | +5.6% | -100.0% | — |
| YoY Change | — | — | — | — | +104.7% | -79.8% | +11.8% | -22.7% | — | +200.0% | +31.8% | +70.6% | +6.6% | +35.2% | -4.5% | +7.8% | +63.0% | -100.0% | -15.0% |
Range$0.00 – $13.20M
CAGR+18.1%
Avg YoY Growth+22.1%
Median YoY Growth+9.8%
Current Streak2 quarters decline
CapEx at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's capex?
- Neurocrine Biosciences (NBIX) reported capex of $9.10M in Q1 2026.
- How has Neurocrine Biosciences's capex changed year-over-year?
- Neurocrine Biosciences's capex decreased by 15.0% year-over-year, from $10.70M to $9.10M.
- What is the long-term trend for Neurocrine Biosciences's capex?
- Over 3 years (2021 to 2025), Neurocrine Biosciences's capex has grown at a 15.9% compound annual growth rate (CAGR), from $23.40M to $36.40M.
- What does capex mean?
- Cash spent on purchasing or maintaining physical assets like machinery and facilities.